SWOG clinical trial number
S9713
A Phase II Trial of Cisplatin/Etoposide and Concurrent, Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation For Limited Stage Small Cell Lung Cancer
Closed
Phase
Accrual
100%
Published
Abbreviated Title
CDDP+VP-16+RT -> Taxol/Carbo in SCLC
Activated
07/01/1998
Closed
08/01/1999
Research committees
Lung Cancer
Publication Information Expand/Collapse
2004
Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713
2002
Phase II (SWOG 9713) trial of cisplatin/etoposide (PE) and concurrent radiotherapy (XRT) followed by paclitaxel/carboplatin (TC) consolidation for limited small cell lung cancer (LSCLC)
Other Clinical Trials
SWOG Clinical Trial Number
S2302
PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
95%
Open
Phase
SWOG Clinical Trial Number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open